IGC Pharma (IGC) Total Liabilities (2011 - 2026)

IGC Pharma (IGC) has reported Total Liabilities for 16 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Liabilities rose 26.77% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 26.77% increase from a year earlier, with the FY2026 full-year figure at $3.1 million, up 26.77% from the prior year.
• Total Liabilities was $3.1 million for Q1 2026 at IGC Pharma, up from $2.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $3.1 million in Q1 2026 and troughed at $1.7 million in Q3 2025.
• A 5-year average of $2.4 million and a median of $2.4 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 32.75% in 2023 and plunged 44.82% in 2025, its largest moves.
• Over 5 years, Total Liabilities stood at $1.8 million in 2022, then rose by 25.84% to $2.2 million in 2023, then increased by 27.79% to $2.8 million in 2024, then decreased by 18.8% to $2.3 million in 2025, then soared by 33.86% to $3.1 million in 2026.
• The last three Total Liabilities figures came in at $3.1 million (Q1 2026), $2.3 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.